. Author manuscript; available in PMC: 2022 Jul 1.

Published in final edited form as: J Allergy Clin Immunol Pract. 2021 Mar 27;9(7):2761–2769.e2. doi: 10.1016/j.jaip.2021.02.053

Table 2.

Baseline asthma and Type-2 inflammatory features, by eosinophil cationic protein (ECP) tertile. Data represent the mean ± standard error of the mean or the number of participants (%).

	Low ECP (<3.12 ng/ml) N=85	Intermediate ECP (3.12–16.22 ng/mL) N=85	High ECP (≥16.23 ng/mL) N=86

Type-2 inflammatory markers
Blood eosinophils (cells/microliter)	230.1 ± 18.3	307.6 ± 27.4^*	375.9 ± 26.8^*
Blood eosinophils (%)	3.47 ± 0.31	5.25 ± 0.49^*	6.23 ± 0.46^*
Exhaled nitric oxide (ppb)	20.8 ± 2.9	36.5 ± 3.6^*	36.9 ± 27.2^*
Serum IgE (kU/L)	119.9 ± 14.8	426.8 ± 273.5^*	1890.6 ± 169.2^*^{^}
% positive aeroallergens (of 12)	12.1 ± 1.8	35.0 ± 2.9^*	43.5 ± 3.0^*^{^}

Exacerbation history (past year)
Any systemic corticosteroid burst	52 (61.2)	48 (56.5)	65 (75.6)^*^{^}
Emergency department visit	38 (44.7)	45 (52.9)	52 (60.5)^*
Hospitalization	21 (24.7)	19 (22.6)	24 (27.9)

Asthma control
ACQ-6 score	0.96 ± 0.15	1.13 ± 0.14	1.14 ± 0.12
ACT or CACT score	20.5 ± 4.2	20.2 ± 4.0	18.8 ± 4.6
Uncontrolled asthma	32 (38.6)	45 (53.6)^*	47 (54.7)^*

PAQLQ score	5.57 ± 0.17	5.57 ± 0.16	5.50 ± 0.14

Lung function
FVC (% predicted)	101.3 ± 1.4	102.4 ± 1.9	101.8 ± 1.8
FEV₁ (% predicted)	94.1 ± 1.4	90.9 ± 2.1^*	88.3 ± 2.0^*
FEV₁/FVC (% predicted)	92.6 ± 1.1	88.2 ± 1.3^*	86.2 ± 1.2^*
FEF₂₅–₇₅ (% predicted)	80.7 ± 2.9	71.4 ± 3.2^*	66.7 ± 2.9^*

Bronchodilator reversibility
FEV₁ absolute reversibility (%)¹	7.4 ± 1.0	11.8 ± 1.3^*	13.0 ± 1.2^*
FEV₁ relative reversibility (%)²	8.2 ± 1.1	15.4 ± 2.0^*	17.0 ± 1.8^*

PC₂₀ (mg/mL methacholine)³	14.9 ± 2.8	5.1 ± 1.6^*	2.5 ± 1.0^*

p<0.05 vs. Low ECP

^{^}

p<0.05 vs. Intermediate ECP

Defined as: % predicted FEV_{1 post-bronchodilator} - % predicted FEV_{1 baseline}

Defined as: (FEV_{1 post-bronchodilator} - FEV_{1 baseline})/FEV_{1 baseline} * 100

Low ECP, n=14; Intermediate ECP, n=19; High ECP, n=23